By: P. Meijer PhD
During the BHS annual meeting, Lieven Annemans (senior professor of health economics at the Faculty of Medicine, Ghent University) posed the rhetorical question: “Are cancer drugs too expensive?” He offered a nuanced perspective by reviewing the advantages and disadvantages of various pricing models, ongoing challenges, and future opportunities.
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
